Offset contracts will allow Moscow city to meet its needs in some essential drugs

17 August 2021
russia_moscow_large-1-

The government of Russia’s capital Moscow city, together with private investors will invest about 10 billion roubles ($137 million) in the construction of at least three large-scale pharmaceutical enterprises, which will produce more than 110 drugs for the city's needs within the next several years, according to recent statements by the Deputy Mayor of Moscow for Economic Policy and Land and Property Relations Vladimir Efimov.

Building of the factories will be carried as part of offset contracts signed with investors, reports The Pharma Letter’s local correspondent.

According to Mr Efimov, the annual purchases of drugs from these factories by the Moscow city will reach 33.5 billion roubles ($463 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics